Update on uveal melanoma: Translational research from biology to clinical practice (Review)
- Authors:
- Miguel A. Ortega
- Oscar Fraile‑Martínez
- Natalio García‑Honduvilla
- Santiago Coca
- Melchor Álvarez‑Mon
- Julia Buján
- Miguel A. Teus
-
Affiliations: Department of Medicine and Medical Specialties, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain, Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain - Published online on: October 22, 2020 https://doi.org/10.3892/ijo.2020.5140
- Pages: 1262-1279
-
Copyright: © Ortega et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Andreoli MT, Mieler WF and Leiderman YI: Epidemiological trends in uveal melanoma. Br J Ophthalmol. 99:1550–1553. 2015. View Article : Google Scholar : PubMed/NCBI | |
Maheshwari A and Finger PT: Cancers of the eye. Cancer Metastasis Rev. 37:677–690. 2018. View Article : Google Scholar : PubMed/NCBI | |
Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH and Nathan PD: Metastatic disease from uveal melanoma: Treatment options and future prospects. Br J Ophthalmol. 101:38–44. 2017. View Article : Google Scholar : | |
Krantz BA, Dave N, Komatsubara KM, Marr BP and Carvajal RD: Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 11:279–289. 2017. View Article : Google Scholar : PubMed/NCBI | |
Seedor RS, Eschelman DJ, Gonsalves CF, Adamo RD, Orloff M, Amjad A, Sharpe-Mills E, Chervoneva I, Shields CL, Shields JA, et al: An Outcome assessment of a single Institution's longitudinal experience with Uveal melanoma patients with liver metastasis. Cancers (Basel). 12:1172020. View Article : Google Scholar | |
Shields CL, Manalac J, Das C, Ferguson K and Shields JA: Choroidal melanoma: Clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol. 25:177–185. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shields CL, Kaliki S, Furuta M, Mashayekhi A and Shields JA: Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 32:1363–1372. 2012. View Article : Google Scholar : PubMed/NCBI | |
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, Lutz JM and Paci E; EUROCARE Working Group: Incidence of uveal melanoma in europe. Ophthalmology. 114:2309–2315. 2007. View Article : Google Scholar : PubMed/NCBI | |
Park SJ, Oh CM, Kim BW, Woo SJ, Cho H and Park KH: Nationwide incidence of ocular melanoma in South Korea by using the national cancer registry database (1999-2011). Invest Ophthalmol Vis Sci. 56:4719–4724. 2015. View Article : Google Scholar : PubMed/NCBI | |
Singh N, Seregard S and Singh AD: Uveal melanoma: Epidemiologic aspects. Clin Ophthalmic Oncol. 53–69. 2019. View Article : Google Scholar | |
Nichols EE, Richmond A and Daniels AB: Disparities in uveal melanoma: Patient characteristics. Semin Ophthalmol. 31:296–303. 2016. View Article : Google Scholar : PubMed/NCBI | |
Nayman T, Bostan C, Logan P and Burnier MN Jr: Uveal melanoma risk Factors: A systematic review of Meta-analyses. Curr Eye Res. 42:1085–1093. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kaliki S, Shields CL and Shields JA: Uveal melanoma: Estimating prognosis. Indian J Ophthalmol. 63:93–102. 2015. View Article : Google Scholar : PubMed/NCBI | |
Al-Jamal RT and Kivelä T: Uveal melanoma among Finnish children and young adults. J AAPOS. 18:61–66. 2014. View Article : Google Scholar : PubMed/NCBI | |
Mallet JD, Gendron SP, Drigeard Desgarnier MC and Rochette PJ: Implication of ultraviolet light in the etiology of uveal melanoma: A review. Photochem Photobiol. 90:15–21. 2014. View Article : Google Scholar | |
Mishra S and Bharagava RN: Toxic and genotoxic effects of hexavalent chromium in environment and its bioremediation strategies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 34:1–32. 2016. View Article : Google Scholar | |
Velazquez N and Jones IS: Ocular and oculodermal melanocytosis associated with Uveal melanoma. Ophthalmology. 90:1472–1476. 1983. View Article : Google Scholar : PubMed/NCBI | |
Plateroti AM, Scavella V, Abdolrahimzadeh B, Plateroti R and Rahimi S: An update on oculodermal melanocytosis and rare associated conditions. Semin Ophthalmol. 32:524–528. 2017. View Article : Google Scholar | |
Shields CL, Kaliki S, Hutchinson A, Nickerson S, Patel J, Kancherla S, Peshtani A, Nakhoda S, Kocher K, Kolbus E, et al: Iris nevus growth into melanoma: Analysis of 1611 consecutive eyes: The ABCDEF guide. Ophthalmology. 120:766–772. 2013. View Article : Google Scholar : PubMed/NCBI | |
Chien JL, Sioufi K, Surakiatchanukul T, Shields JA and Shields CL: Choroidal nevus: A review of prevalence, features, genetics, risks, and outcomes. Curr Opin Ophthalmol. 28:228–237. 2017. View Article : Google Scholar : PubMed/NCBI | |
Rodríguez A, Dueñas-Gonzalez A and Delgado-Pelayo S: Clinical presentation and management of uveal melanoma. Mol Clin Oncol. 5:675–677. 2016. View Article : Google Scholar | |
Nezu N, Goto H, Umazume K, Ueda S and Shibata M: Clinical analysis of uveal melanoma. Nippon Ganka Gakkai Zasshi. 121:413–418. 2017.In Japanese. PubMed/NCBI | |
Callender GR: Malignant melanotic tumors of the eye. A study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol. 36:131–140. 1931. | |
McLean IW, Foster WD, Zimmerman LE and Gamel JW: Modifications of Callender's classification of uveal melanoma at the armed forces institute of pathology. Am J Ophthalmol. 96:502–509. 1983. View Article : Google Scholar : PubMed/NCBI | |
Seddon JM, Polivogianis L, Hsieh CC, Albert DM, Gamel JW and Gragoudas ES: Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. Arch Ophthalmol. 105:801–806. 1987. View Article : Google Scholar : PubMed/NCBI | |
Seregard S and Kock E: Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of Long-term survival with minimized loss to Follow-up. Acta Ophthalmol Scand. 73:340–344. 1995. View Article : Google Scholar : PubMed/NCBI | |
Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, Yi H and Moore KC: The morpho-logic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: A matched Case-control study. Hum Pathol. 23:1298–1305. 1992. View Article : Google Scholar : PubMed/NCBI | |
Al-Jamal RT, Mäkitie T and Kivelä T: Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest Ophthalmol Vis Sci. 44:2381–2389. 2003. View Article : Google Scholar : PubMed/NCBI | |
Moshari A and McLean IW: Uveal melanoma: Mean of the longest nucleoli measured on Silver-stained sections. Invest Ophthalmol Vis Sci. 42:1160–1163. 2001.PubMed/NCBI | |
All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ and Larsson O: Insulin-like growth Factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 43:1–8. 2002.PubMed/NCBI | |
Karlsson M, Boeryd B, Carstensen J, Frånlund B, Gustafsson B, Kågedal B, Sun XF and Wingren S: Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma. Eur J Cancer. 32A:357–362. 1996. View Article : Google Scholar : PubMed/NCBI | |
Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP and Jager MJ: Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 52:643–650. 2011. View Article : Google Scholar | |
Bronkhorst IH and Jager MJ: Uveal melanoma: The inflammatory microenvironment. J Innate Immun. 4:454–462. 2012. View Article : Google Scholar : PubMed/NCBI | |
Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH and Jager MJ: Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 38:1865–1872. 1997.PubMed/NCBI | |
Onken MD, Worley LA, Ehlers JP and Harbour JW: Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 64:7205–7209. 2004. View Article : Google Scholar : PubMed/NCBI | |
Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, et al: Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 32:204–220.e15. 2017. View Article : Google Scholar : PubMed/NCBI | |
Reichstein D: New concepts in the molecular understanding of uveal melanoma. Curr Opin Ophthalmol. 28:219–227. 2017. View Article : Google Scholar : PubMed/NCBI | |
Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN and Harbour JW: PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 22:1234–1242. 2016. View Article : Google Scholar : PubMed/NCBI | |
Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S and Harbour JW: Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas. Oncotarget. 7:59209–59219. 2016. View Article : Google Scholar : PubMed/NCBI | |
Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG and Harbour JW: Driver mutations in uveal melanoma: Associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 134:728–733. 2016. View Article : Google Scholar : PubMed/NCBI | |
Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, et al: Development of metastatic disease after enrolment in the COMS trials for treatment of choroidal melanoma: Collaborative ocular melanoma study group report no 26. Arch Ophthalmol. 123:1639–1643. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ramaiya KJ and Harbour JW: Current management of uveal melanoma. Expert Rev Ophthalmol. 2:939–946. 2007. View Article : Google Scholar | |
Pandiani C, Béranger GE, Leclerc J, Ballotti R and Bertolotto C: Focus on cutaneous and uveal melanoma specificities. Genes Dev. 31:724–743. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ny L, Nyakas M, Hernberg M, Koivunen J, Oddershede L, Yoon MR, Wang X, Guyot P and Geisler J: BRAF mutation as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis. J Clin Oncol. 36:e215662018. View Article : Google Scholar | |
Wu J, Brunner G and Celebi JT: A melanoma subtype: Uveal melanoma. J Am Acad Dermatol. 64:1185–1186. 2011. View Article : Google Scholar : PubMed/NCBI | |
Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A and Pringle JH: High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer. 111:705–710. 2004. View Article : Google Scholar : PubMed/NCBI | |
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, et al: Mutations in GNA11 in uveal melanoma. N Engl J Med. 363:2191–2199. 2010. View Article : Google Scholar : PubMed/NCBI | |
Van der Kooij MK, Speetjens FM, van der Burg SH and Kapiteijn E: Uveal versus cutaneous melanoma; Same origin, very distinct tumor types. Cancers (Basel). 11:8452019. View Article : Google Scholar | |
Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, Zhang JQ, Walczak EG, Kazmi MA, Taylor BS, et al: Recurrent activating mutations of G-Protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 48:675–680. 2016. View Article : Google Scholar : PubMed/NCBI | |
Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, et al: Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 7:4624–4631. 2016. View Article : Google Scholar | |
Dono M, Angelini G, Cecconi M, Amaro A, Esposito AI, Mirisola V, Maric I, Lanza F, Nasciuti F, Viaggi S, et al: Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: Detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer. 110:1058–1065. 2014. View Article : Google Scholar : PubMed/NCBI | |
Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al: TERT promoter mutations in familial and sporadic melanoma. Science. 339:959–961. 2013. View Article : Google Scholar : PubMed/NCBI | |
Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Süsskind D, Grabellus F, Zimmer L, Hillen U, et al: TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer. 109:497–501. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bronkhorst IH and Jager MJ: Inflammation in uveal melanoma. Eye (Lond). 27:217–223. 2013. View Article : Google Scholar | |
Maat W, Ly LV, Jordanova ES, Wolff-Rouendaal D, Schalij-Delfos NE and Jager MJ: Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 49:505–510. 2008. View Article : Google Scholar : PubMed/NCBI | |
Mahoney KM, Freeman GJ and McDermott DF: The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 37:764–782. 2015. View Article : Google Scholar : PubMed/NCBI | |
Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE and Abraham I: Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: A systematic review and Meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med. 5:1481–1491. 2016. View Article : Google Scholar : PubMed/NCBI | |
Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ and Sato T: PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 9:1323–1330. 2017. View Article : Google Scholar : PubMed/NCBI | |
Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S and Kiessling R: Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer. 116:2224–2233. 2010.PubMed/NCBI | |
Lagouros E, Salomao D, Thorland E, Hodge DO, Vile R and Pulido JS: Infiltrative T regulatory cells in enucleated uveal melanomas. Trans Am Ophthalmol Soc. 107:223–228. 2009. | |
Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH and Jager MJ: Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 53:5370–5378. 2012. View Article : Google Scholar : PubMed/NCBI | |
Petralia MC, Mazzon E, Fagone P, Russo A, Longo A, Avitabile T, Nicoletti F, Reibaldi M and Basile MS: Characterization of the pathophysiological role of CD47 in Uveal melanoma. Molecules. 24:24502019. View Article : Google Scholar : | |
Basile MS, Mazzon E, Russo A, Mammana S, Longo A, Bonfiglio V, Fallico M, Caltabiano R, Fagone P, Nicoletti F, et al: Differential modulation and prognostic values of immune-escape genes in uveal melanoma. PLoS One. 14:e02102762019. View Article : Google Scholar : PubMed/NCBI | |
Ding L, Lu S and Li Y: Regulation of PD-1/PD-L1 pathway in cancer by noncoding RNAs. Pathol Oncol Res. 26:651–663. 2020. View Article : Google Scholar | |
Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ and Sato T: PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 9:1323–1330. 2017. View Article : Google Scholar : PubMed/NCBI | |
Durante MA, Rodriguez DA, Kurtenbach S, Kuznetsov JN, Sanchez MI, Decatur CL, Snyder H, Feun LG, Livingstone AS and Harbour JW: Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nat Commun. 11(496)2020. View Article : Google Scholar : PubMed/NCBI | |
Babchia N, Landreville S, Clément B, Coulouarn C and Mouriaux F: The bidirectional crosstalk between metastatic uveal melanoma cells and hepatic stellate cells engenders an inflammatory microenvironment. Exp Eye Res. 181:213–222. 2019. View Article : Google Scholar : PubMed/NCBI | |
Giulietti M, Vivenzio V, Piva F, Principato G, Bellantuono C and Nardi B: How much do we know about the coupling of G-proteins to serotonin receptors? Mol Brain. 7:492014. View Article : Google Scholar : PubMed/NCBI | |
Tschentscher F, Hüsing J, Holter T, Kruse E, Dresen IG, Jöckel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, et al: Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 63:2578–2584. 2003.PubMed/NCBI | |
Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, Martins C, Fernandes BF and Burnier MN Jr: Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res. 14:951–956. 2008. View Article : Google Scholar : PubMed/NCBI | |
O'Hayre M, Degese MS and Gutkind JS: Novel insights into G protein and G Protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 27:126–135. 2014. View Article : Google Scholar : PubMed/NCBI | |
Liu H, Lei C, Long K, Yang X, Zhu Z, Zhang L and Liu J: Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling. Oncol Rep. 34:295–301. 2015. View Article : Google Scholar : PubMed/NCBI | |
Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, et al: Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 25:831–845. 2014. View Article : Google Scholar : PubMed/NCBI | |
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C and Bowcock AM: Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 330:1410–1413. 2010. View Article : Google Scholar : PubMed/NCBI | |
Coupland SE, Lake SL, Zeschnigk M and Damato BE: Molecular pathology of uveal melanoma. Eye (Lond). 27:230–242. 2013. View Article : Google Scholar | |
Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P and Davidorf FH: Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 48:856–859. 2011. View Article : Google Scholar : PubMed/NCBI | |
Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW and Müller J: Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature. 465:243–247. 2010. View Article : Google Scholar : PubMed/NCBI | |
Eletr ZM and Wilkinson KD: An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys. 60:3–11. 2001. View Article : Google Scholar | |
He M, Chaurushiya MS, Webster JD, Kummerfeld S, Reja R, Chaudhuri S, Chen YJ, Modrusan Z, Haley B, Dugger DL, et al: Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1. Science. 364:283–285. 2019.PubMed/NCBI | |
Park JJ, Diefenbach RJ, Joshua AM, Kefford RF, Carlino MS and Rizos H: Oncogenic signaling in uveal melanoma. Pigment Cell Melanoma Res. 31:661–672. 2018. View Article : Google Scholar : PubMed/NCBI | |
Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM and Harbour JW: BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 13:3712013. View Article : Google Scholar : PubMed/NCBI | |
Oliva M, Rullan AJ and Piulats JM: Uveal melanoma as a target for Immune therapy. Ann Transl Med. 4:1722016. View Article : Google Scholar | |
Szalai E, Wells JR, Ward L and Grossniklaus HE: Uveal melanoma nuclear BRCA1-associated Protein-1 immunoreactivity is an indicator of metastasis. Ophthalmology. 125:203–209. 2018. View Article : Google Scholar | |
Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, et al: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 3:1122–1129. 2013. View Article : Google Scholar : PubMed/NCBI | |
Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S and Pfeffer U: The biology of uveal melanoma. Cancer Metastasis Rev. 36:109–140. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yavuzyigitoglu S, Koopmans AE, Verdijk RM, Vaarwater J, Eussen B, van Bodegom A, Paridaens D, Kiliç E and de Klein A; Rotterdam Ocular Melanoma Study Group: Uveal melanomas with SF3B1 mutations: A distinct subclass associated with Late-onset metastases. Ophthalmology. 123:1118–1128. 2016. View Article : Google Scholar : PubMed/NCBI | |
Coltri PP, Dos Santos MGP and da Silva GHG: Splicing and cancer: Challenges and opportunities. Wiley Interdiscip Rev RNA. 10:e15272019. View Article : Google Scholar : PubMed/NCBI | |
Alsafadi S, Mobuchon L, Rodrigues M and Stern MH: Uveal melanoma, a model disease for splicing alterations and oncogenesis. Med Sci (Paris). 34:155–160. 2018.In French. View Article : Google Scholar | |
Tanaka A, Kobayashi S, Xiao M and Inoue D: Understanding and therapeutic targeting of aberrant mRNA splicing mechanisms in oncogenesis. Rinsho Ketsueki. 61:643–650. 2020.In Japanese. | |
Freemantle SJ, Spinella MJ and Dmitrovsky E: Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene. 22:7305–7315. 2003. View Article : Google Scholar : PubMed/NCBI | |
Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M and Bernards R: The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 122:835–847. 2005. View Article : Google Scholar : PubMed/NCBI | |
Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, Fereday S, Mitchell C, Chiew YE, Hendley J, et al: EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-grade serous ovarian carcinomas. Cancer Res. 77:4268–4278. 2017. View Article : Google Scholar : PubMed/NCBI | |
Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, et al: EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and C-MYC. Cancer Discov. 9:264–281. 2019. View Article : Google Scholar : | |
Bagnato A and Rosanò L: The endothelin axis in cancer. Int J Biochem Cell Biol. 40:1443–1451. 2008. View Article : Google Scholar : PubMed/NCBI | |
Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ and Maguire JJ: Endothelin. Pharmacol Rev. 68:357–418. 2016. View Article : Google Scholar : PubMed/NCBI | |
Pla P, Alberti C, Solov'eva O, Pasdar M, Kunisada T and Larue L: Ednrb2 orients cell migration towards the dorsolateral neural crest pathway and promotes melanocyte differentiation. Pigment Cell Res. 18:181–187. 2005. View Article : Google Scholar : PubMed/NCBI | |
Smith SL, Damato BE, Scholes AG, Nunn J, Field JK and Heighway J: Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. Br J Cancer. 87:1308–1313. 2002. View Article : Google Scholar : PubMed/NCBI | |
Urtatiz O and Van Raamsdonk CD: Gnaq and Gna11 in the endothelin signaling pathway and melanoma. Front Genet. 7:592016. View Article : Google Scholar : PubMed/NCBI | |
Mallikarjuna K, Pushparaj V, Biswas J and Krishnakumar S: Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study. Curr Eye Res. 32:281–290. 2007. View Article : Google Scholar : PubMed/NCBI | |
Franco R, Botti G, Mascolo M, Loquercio G, Liguori G, Ilardi G, Losito S, La Mura A, Calemma R, Ierano C, et al: CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. Front Biosci (Elite Ed). 2:13–21. 2010. View Article : Google Scholar | |
Vivet-Noguer R, Tarin M, Roman-Roman S and Alsafadi S: Emerging therapeutic opportunities based on current knowledge of uveal melanoma Biology. Cancers (Basel). 11:10192019. View Article : Google Scholar | |
Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T and Aplin AE: Co-targeting HGF-CMET Signaling with MEK inhibitors in metastatic uveal melanoma. Mol Cancer Ther. 116:516–528. 2017. View Article : Google Scholar | |
Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH and Eng C: High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol. 24:288–295. 2006. View Article : Google Scholar | |
Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L and Kolb HC: The clinical importance of assessing tumor hypoxia: Relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 21:1516–1554. 2014. View Article : Google Scholar : PubMed/NCBI | |
Semenza GL: HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010. View Article : Google Scholar : | |
Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG and Wang B: Hypoxia inducible factor pathway inhibitors as anti-cancer therapeutics. Future Med Chem. 5:553–572. 2013. View Article : Google Scholar : PubMed/NCBI | |
Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, et al: Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 28:135–147. 2015. View Article : Google Scholar : | |
Keith B, Johnson RS and Simon MC: HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 12:9–22. 2011. View Article : Google Scholar : PubMed/NCBI | |
Asnaghi L, Lin MH, Lim KS, Lim KJ, Tripathy A, Wendeborn M, Merbs SL, Handa JT, Sodhi A, Bar EE and Eberhart CG: Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation. PLoS One. 9:e1053722014. View Article : Google Scholar : PubMed/NCBI | |
Mouriaux F, Sanschagrin F, Diorio C, Landreville S, Comoz F, Petit E, Bernaudin M, Rousseau AP, Bergeron D and Morcos M: Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci. 55:1277–1283. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hu K, Babapoor-Farrokhran S, Rodrigues M, Deshpande M, Puchner B, Kashiwabuchi F, Hassan SJ, Asnaghi L, Handa JT, Merbs S, et al: Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. Oncotarget. 7:7816–7828. 2016. View Article : Google Scholar : PubMed/NCBI | |
Dong L, You S, Zhang Q, Osuka S, Devi NS, Kaluz S, Ferguson JH, Yang H, Chen G, Wang B, et al: Arylsulfonamide 64B inhibits Hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma. Clin Cancer Res. 25:2206–2218. 2019. View Article : Google Scholar : | |
Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, Versluis M, Kroes WGM, van der Velden PA, Verdijk RM and Jager MJ: Tumour angiogenesis in uveal melanoma is related to genetic evolution. Cancers (Basel). 11:9792019. View Article : Google Scholar | |
Brouwer NJ, Wierenga APA, Gezgin G, Marinkovic M, Luyten GPM, Kroes WGM, Versluis M, van der Velden PA, Verdijk RM and Jager MJ: Ischemia is related to tumour genetics in uveal melanoma. Cancers (Basel). 11:10042019. View Article : Google Scholar | |
Spector A: Review: Oxidative stress and disease. J Ocul Pharmacol Ther. 16:193–201. 2000. View Article : Google Scholar : PubMed/NCBI | |
Di Meo S, Reed TT, Venditti P and Victor VM: Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev. 2016:12450492016. View Article : Google Scholar : PubMed/NCBI | |
Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, et al: An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 491:449–453. 2012. View Article : Google Scholar : PubMed/NCBI | |
Reuter S, Gupta SC, Chaturvedi MM and Aggarwal BB: Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 49:1603–1616. 2010. View Article : Google Scholar : PubMed/NCBI | |
Andrisic L, Dudzik D, Barbas C, Milkovic L, Grune T and Zarkovic N: Short overview on metabolomics approach to study pathophysiology of oxidative stress in cancer. Redox Biol. 14:47–58. 2018. View Article : Google Scholar | |
Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ and Morrison SJ: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 527:186–1891. 2015. View Article : Google Scholar : PubMed/NCBI | |
Dithmer M, Kirsch AM, Gräfenstein L, Wang F, Schmidt H, Coupland SE, Fuchs S, Roider J and Klettner AK: Uveal melanoma cell under oxidative Stress-influence of VEGF and VEGF-inhibitors. Klin Monbl Augenheilkd. 236:295–307. 2019.In German. View Article : Google Scholar | |
Costa FF: Epigenomics in cancer management. Cancer Manag Res. 2:255–265. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yang X, Gao L and Zhang S: Comparative Pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief Bioinform. 18:761–773. 2017. | |
Maat W, van der Velden PA, Out-Luiting C, Plug M, Dirks- Mulder A, Jager MJ and Gruis NA: Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci. 48:486–490. 2007. View Article : Google Scholar : PubMed/NCBI | |
Dammann RH, Richter AM, Jiménez AP, Woods M, Küster M and Witharana C: Impact of natural compounds on DNA methylation levels of the tumor suppressor Gene RASSF1A in cancer. Int J Mol Sci. 18:21602017. View Article : Google Scholar : | |
Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA and van der Velden PA: Epigenetic regulation identifies RASEF as a Tumor-suppressor gene in uveal melanoma. Invest Ophthalmol Vis Sci. 49:1291–1298. 2008. View Article : Google Scholar : PubMed/NCBI | |
Venza M, Visalli M, Biondo C, Lentini M, Catalano T, Teti D and Venza I: Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma. Biochim Biophys Acta. 1849:247–256. 2015. View Article : Google Scholar | |
Venza M, Visalli M, Catalano T, Fortunato C, Oteri R, Teti D and Venza I: Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis Factor-related Apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. Biochem Biophys Res Commun. 441:743–750. 2013. View Article : Google Scholar : PubMed/NCBI | |
Van der Veiden PA, Metzelaar-Blok JA, Bergman W, Hurks H, Frants RR, Gruis NA and Jager MJ: Promoter Hypermethylation: A common cause of reduced P16(INK4a) expression in uveal melanoma. Cancer Res. 61:5303–5306. 2001. | |
Li Y, Jia R and Ge S: Role of Epigenetics in Uveal Melanoma. Int J Biol Sci. 13:426–4332. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yang ZK, Yang JY, Xu ZZ and Yu WH: DNA Methylation and uveal melanoma. Chin Med J (Engl). 131:845–851. 2018. View Article : Google Scholar | |
Audia JE and Campbell RM: Histone modifications and cancer. Cold Spring Harb Perspect Biol. 8:a0195212016. View Article : Google Scholar : PubMed/NCBI | |
Ding X, Wang X, Lin M, Xing Y, Ge S, Jia R, Zhang H, Fan X and Li J: PAUPAR lncRNA suppresses tumourigenesis by H3K4 demethylation in uveal melanoma. FEBS Lett. 590:1729–1738. 2016. View Article : Google Scholar : PubMed/NCBI | |
Dong R, Liu J, Sun W and Ping W: Comprehensive analysis of aberrantly expressed profiles of lncRNAs and miRNAs with associated ceRNA Network in lung adenocarcinoma and lung squamous cell carcinoma. Pathol Oncol Res. 26:1935–1945. 2020. View Article : Google Scholar : PubMed/NCBI | |
Catalanotto C, Cogoni C and Zardo G: MicroRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci. 17:17122016. View Article : Google Scholar : | |
Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI | |
Mishra S, Yadav T and Rani V: Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 98:12–23. 2016. View Article : Google Scholar | |
Lopez-Rincon A, Martinez-Archundia M, Martinez-Ruiz GU, Schoenhuth A and Tonda A: Automatic discovery of 100-miRNA signature for cancer classification using ensemble feature selection. BMC Bioinformatics. 20:4802019. View Article : Google Scholar : PubMed/NCBI | |
Li Z, Yu X, Shen J and Jiang Y: MicroRNA dysregulation in uveal melanoma: A new player enters the game. Oncotarget. 6:4562–458. 2015. View Article : Google Scholar : PubMed/NCBI | |
Yang C and Wei W: The miRNA expression profile of the uveal melanoma. Sci China Life Sci. 54:351–358. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wang YC, Yang X, Wei WB and Xu XL: Role of microRNA-21 in uveal melanoma cell invasion and metastasis by regulating p53 and its downstream protein. Int J Ophthalmol. 11:1258–1268. 2018. | |
Radhakrishnan A, Badhrinarayanan N, Biswas J and Krishnakumar S: Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol Vis. 15:2146–2154. 2009.PubMed/NCBI | |
Peng J, Liu H and Liu C: MiR-155 Promotes uveal melanoma cell proliferation and invasion by regulating NDFIP1 expression. Technol Cancer Res Treat. 16:1160–1167. 2017. View Article : Google Scholar | |
Li Y, Huang Q, Shi X, Jin X, Shen L, Xu X and Wei W: MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate 1. Chin Med J (Engl). 127:1410–1416. 2014. | |
Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, Lu F, Tu L and Qu J: MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci. 50:1559–1565. 2009. View Article : Google Scholar | |
Dong F and Lou D: MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 18:537–546. 2012.PubMed/NCBI | |
Serocki M, Bartoszewska S, Janaszak-Jasiecka A, Ochocka RJ, Collawn JF and Bartoszewski R: miRNAs regulate the HIF switch during hypoxia: A novel therapeutic target. Angiogenesis. 21:183–202. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sun L, Wang Q, Gao X, Shi D, Mi S and Han Q: MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. FEBS Lett. 589:2791–2796. 2015. View Article : Google Scholar : PubMed/NCBI | |
Ling J, Lu P, Zhang Y, Jiang S and Zhang Z: MiR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN. Genet Mol Res. 16:gmr160390672017. View Article : Google Scholar | |
Liu Y, Huo Y, Wang D, Tai Y, Li J, Pang D, Zhang Y, Zhao W, Du N and Huang Y: MiR-216a-5p/Hexokinase 2 axis regulates uveal melanoma growth through modulation of Warburg effect. Biochem Biophys Res Commun. 50:885–892. 2018. View Article : Google Scholar | |
Singh AD, Turell ME and Topham AK: Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kaliki S and Shields CL: Uveal melanoma: Relatively rare but deadly cancer. Eye (Lond). 31:241–257. 2017. View Article : Google Scholar | |
Triozzi PL and Singh AD: Blood biomarkers for uveal melanoma. Future Oncol. 8:205–215. 2012. View Article : Google Scholar : PubMed/NCBI | |
Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY and Bidard FC: Circulating tumor cells: Clinical validity and utility. Int J Clin Oncol. 22:421–430. 2017. View Article : Google Scholar : PubMed/NCBI | |
Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, Lee RJ, Garner G, Dhomen N, Lorigan PC and Marais R: Plasma total Cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 88:1–9. 2018. View Article : Google Scholar : | |
Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M and Sato T: Arterial blood, rather than venous blood, is a better source for circulating melanoma cells. EBioMedicine. 2:1821–1826. 2015. View Article : Google Scholar | |
Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, Cassoux N, Desjardins L, Milder M, Vaucher I, et al: Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 134:1207–1213. 2014. View Article : Google Scholar | |
Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Thiel E, Foerster MH and Keilholz U: Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology. 80:57–62. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tura A, Merz H, Reinsberg M, Lüke M, Jager MJ, Grisanti S and Lüke J: Analysis of monosomy-3 in immunomagnetically-isolated circulating melanoma cells in uveal melanoma patients. Pigment Cell Melanoma Res. 29:583–589. 2016. View Article : Google Scholar : PubMed/NCBI | |
Achberger S, Aldrich W, Tubbs R, Crabb JW, Singh AD and Triozzi PL: Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol. 58:182–186. 2014. View Article : Google Scholar : | |
Russo A, Caltabiano R, Longo A, Avitabile T, Franco LM, Bonfiglio V, Puzzo L and Reibaldi M: Increased levels of miRNA-146a in serum and histologic samples of patients with uveal melanoma. Front Pharmacol. 7:4242016. View Article : Google Scholar : PubMed/NCBI | |
Eldh M, Olofsson Bagge R, Lässer C, Svanvik J, Sjöstrand M, Mattsson J, Lindnér P, Choi DS, Gho YS and Lötvall J: MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. BMC Cancer. 14:9622014. View Article : Google Scholar : PubMed/NCBI | |
Stark MS, Gray ES, Isaacs T, Chen FK, Millward M, McEvoy A, Zaenker P, Ziman M, Soyer HP, Glasson WJ, et al: Panel of Circulating MicroRNAs detects uveal melanoma with high precision. Transl Vis Sci Technol. 8:122019. View Article : Google Scholar | |
Peng L, Cantor DI, Huang C, Wang K, Baker MS and Nice EC: Tissue and plasma proteomics for early stage cancer detection. Mol Omics. 14:405–423. 2018. View Article : Google Scholar : PubMed/NCBI | |
Karimi P, Shahrokni A and Ranjbar MR: Implementation of proteomics for cancer research: Past, present, and future. Asian Pac J Cancer Prev. 15:2433–2438. 2014. View Article : Google Scholar : PubMed/NCBI | |
Reiniger IW, Schaller UC, Haritoglou C, Hein R, Bosserhoff AK, Kampik A and Mueller AJ: 'Melanoma inhibitory activity' (MIA): A promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 243:1161–1166. 2005. View Article : Google Scholar : PubMed/NCBI | |
Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R and Schaller UC: Osteopontin and 'melanoma inhibitory activity': Comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica. 223:239–243. 2009. View Article : Google Scholar : PubMed/NCBI | |
Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R and Pe'er J: Serum markers to detect metastatic uveal melanoma. Anticancer Res. 27:1897–1900. 2007.PubMed/NCBI | |
Missotten GS, Tang NE, Korse CM, Hurks HM, de Wolff-Rouendaal D, Keunen JE, Jager MJ and Bonfrer JM: Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Arch Ophthalmol. 121:1117–1119. 2003. View Article : Google Scholar : PubMed/NCBI | |
Strobel K, Bode B, Dummer R, Veit-Haibach P, Fischer DR, Imhof L, Goldinger S, Steinert HC and von Schulthess GK: Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging. 36:1774–1782. 2009. View Article : Google Scholar : PubMed/NCBI | |
Suesskind D, Schatz A, Schnichels S, Coupland SE, Lake SL, Wissinger B, Bartz-Schmidt KU and Henke-Fahle S: GDF-15: A novel serum marker for metastases in uveal melanoma patients. Graefes Arch Clin Exp Ophthalmol. 250:887–895. 2012. View Article : Google Scholar | |
Bande MF, Santiago M, Blanco MJ, Mera P, Capeans C, Rodríguez-Alvarez MX, Pardo M and Piñeiro A: Serum DJ-1/PARK 7 is a potential biomarker of choroidal nevi transformation. Invest Ophthalmol Vis Sci. 53:62–67. 2012. View Article : Google Scholar | |
Bande MF, Santiago M, Mera P, Piulats JM, Blanco MJ, Rodríguez-Álvarez MX, Capeans C, Piñeiro A and Pardo M: ME20-S as a potential biomarker for the evaluation of uveal melanoma. Invest Ophthalmol Vis Sci. 56:7007–7011. 2015. View Article : Google Scholar : PubMed/NCBI | |
Barisione G, Fabbi M, Gino A, Queirolo P, Orgiano L, Spano L, Picasso V, Pfeffer U, Mosci C, Jager MJ, et al: Potential Role of Soluble c-Met as a New candidate biomarker of metastatic uveal melanoma. JAMA Ophthalmol. 133:1013–1021. 2015. View Article : Google Scholar : PubMed/NCBI | |
Angi M, Kalirai H, Prendergast S, Simpson D, Hammond DE, Madigan MC, Beynon RJ and Coupland SE: In-depth proteomic profiling of the uveal melanoma secretome. Oncotarget. 7:49623–49635. 2016. View Article : Google Scholar : PubMed/NCBI | |
Crabb JW, Hu B, Crabb JS, Triozzi P, Saunthararajah Y, Tubbs R and Singh AD: iTRAQ quantitative proteomic comparison of metastatic and non-metastatic uveal melanoma tumors. PLoS One. 10:e01355432015. View Article : Google Scholar : PubMed/NCBI | |
Shi XY, Li Q, Wei WB and Tao LM: Peptidome profiling of human serum of uveal melanoma patients based on magnetic bead fractionation and mass spectrometry. Int J Ophthalmol. 10:939–947. 2017.PubMed/NCBI | |
Song J, Merbs SL, Sokoll LJ, Chan DW and Zhang Z: A multi-plex immunoassay of serum biomarkers for the detection of uveal melanoma. Clin Proteomics. 16:102019. View Article : Google Scholar | |
Corrêa ZM: Assessing prognosis in uveal melanoma. Cancer Control. 23:93–98. 2016. View Article : Google Scholar : PubMed/NCBI | |
Balasubramanya R, Selvarajan SK, Cox M, Joshi G, Deshmukh S, Mitchell DG and O'Kane P: Imaging of ocular melanoma metastasis. Br J Radiol. 89:201600922016. View Article : Google Scholar : PubMed/NCBI | |
Smit KN, Jager MJ, de Klein A and Kiliç E: Uveal melanoma: Towards a molecular understanding. Prog Retin Eye Res. 75:1008002020. View Article : Google Scholar | |
Schopper VJ and Correa ZM: Clinical application of genetic testing for posterior uveal melanoma. Int J Retina Vitreous. 2:42016. View Article : Google Scholar : PubMed/NCBI | |
Damato B, Dopierala JA and Coupland SE: Genotypic profiling of 452 choroidal melanomas with multiplex Ligation-dependent probe amplification. Clin Cancer Res. 16:6083–6092. 2010. View Article : Google Scholar : PubMed/NCBI | |
Dogrusöz M, Jager MJ and Damato B: Uveal melanoma treatment and prognostication. Asia Pac J Ophthalmol (Phila). 6:186–196. 2017. | |
Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr, Altaweel MM, Bardenstein DS, Finger PT, et al: Collaborative Ocular Oncology Group report number 1: Prospective validation of a Multi-gene prognostic assay in uveal melanoma. Ophthalmology. 119:1596–1603. 2012. View Article : Google Scholar : PubMed/NCBI | |
Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Cisarova K, Pescini-Gobert R, Raynaud F, Zografos L, Schalenbourg A, Speiser D, et al: Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am J Hum Genet. 99:1190–1198. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE and Patel SP: Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 122:2299–2312. 2016. View Article : Google Scholar : PubMed/NCBI | |
Frizziero L, Midena E, Trainiti S, Londei D, Bonaldi L, Bini S and Parrozzani R: Uveal melanoma biopsy: A review. Cancers (Basel). 11:10752019. View Article : Google Scholar | |
Erim Y, Scheel J, Breidenstein A, Metz CH, Lohmann D, Friederich HC and Tagay SP: Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: Protocol of a controlled prospective clinical observational. BMC Cancer. 16:4082016. View Article : Google Scholar | |
Damato B and Coupland SE: Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol. 127:423–429. 2009. View Article : Google Scholar : PubMed/NCBI | |
Harbour JW: Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol. 148:823–829.e1. 2009. View Article : Google Scholar : PubMed/NCBI | |
Aaberg TM Jr, Cook RW, Oelschlager K, Maetzold D, Rao PK and Mason JO III: Current clinical practice: Differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 8:2449–2460. 2014. View Article : Google Scholar | |
Schoenfield L, Pettay J, Tubbs RR and Singh AD: Variation of monosomy 3 status within uveal melanoma. Arch Pathol Lab Med. 133:1219–1222. 2009.PubMed/NCBI | |
Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, Fenwick S, Kirkpatrick L, Li O, Marshall E, et al: Uveal melanoma UK national guidelines. Eur J Cancer. 51:2404–2412. 2015. View Article : Google Scholar : PubMed/NCBI | |
Álvarez-Rodríguez B, Latorre A, Posch C and Somoza Á: Recent advances in uveal melanoma treatment. Med Res Rev. 37:1350–1372. 2017. View Article : Google Scholar : PubMed/NCBI | |
Damato BE, Dukes J, Goodall H and Carvajal RD: Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel). 11:9712019. View Article : Google Scholar | |
Schank TE and Hassel JC: Immunotherapies for the treatment of uveal melanoma-history and future. Cancers (Basel). 11:10482019. View Article : Google Scholar | |
Bol K, van den Bosch T, Schreibelt G, Punt C, Figdor C, Paridaens D and de Vries J: Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients. J Immuno Ther Cancer:. 3:2015. | |
Thota R, Johnson DB and Sosman JA: Trametinib in the treatment of melanoma. Expert Opin Biol Ther. 15:735–747. 2015. View Article : Google Scholar : PubMed/NCBI | |
Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, et al: Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, randomized trial (SUMIT). J Clin Oncol. 36:1232–1239. 2018. View Article : Google Scholar : PubMed/NCBI | |
Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, et al: New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging. Cancer Res. 78:542–557. 2018. View Article : Google Scholar : | |
Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T and Aplin AE: Co-targeting HGF/cMET Signaling with MEK inhibitors in metastatic uveal melanoma. Mol Cancer Ther. 16:516–528. 2017. View Article : Google Scholar : PubMed/NCBI | |
Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, et al: HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. Clin Cancer Res. 25:5686–5701. 2019. View Article : Google Scholar | |
Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM and Harbour JW: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 18:408–416. 2012. View Article : Google Scholar : | |
Bonnal S, Vigevani L and Valcárcel J: The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Dis. 11:847–859. 2012. View Article : Google Scholar | |
Yoshimoto R, Kaida D, Furuno M, Burroughs AM, Noma S, Suzuki H, Kawamura Y, Hayashizaki Y, Mayeda A and Yoshida M: Global analysis of pre-mRNA subcellular localization following splicing inhibition by spliceostatin A. RNA. 23:47–57. 2017. View Article : Google Scholar : | |
Wu G, Fan L, Edmonson MN, Shaw T, Boggs K, Easton J, Rusch MC, Webb TR, Zhang J and Potter PM: Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping. RNA. 24:1056–1066. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhou Z, Gong Q, Wang Y, Li M, Wang L, Ding H and Li P: The biological function and clinical significance of SF3B1 mutations in cancer. Biomarker Res. 8(38)2020. View Article : Google Scholar | |
García M, Moreno R, Gil-Martin M, Cascallò M, de Olza MO, Cuadra C, Piulats JM, Navarro V, Domenech M, Alemany R and Salazar R: A Phase 1 Trial of Oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 30:352–364. 2019. View Article : Google Scholar |